Home 2015
Archives
FDA Approves Odomzo for Recurring Basal Cell Carcinoma
Medication is designed to inhibit the Hedgehog pathway
CDC: Stillbirths Now Outnumber Infant Deaths in U.S.
Experts point to dropping infant death rates, racial disparities in care, and fertility treatments as factors
CDC: U.S. Teens Waiting Longer to Have Sex
Report finds fewer than half of those aged 15 to 19 have had intercourse
CMS Finalizes Decision to Cover HPV Testing for Cervical Cancer
AAFP encouraged CMS to consider coverage and follow through on proposal
CMS May Adopt Doctors’ Calls for End-of-Life Counseling
Two new codes would be established; would be used for conversations about care options
AMA Suggests Ways to Encourage Use of Patient Portals
Suggestions include training staff on portal use; showing patients how to use the portal
Trend Alert: Sunburn ‘Art’ Growing Presence on Social Media
Experts warn against the dangers of the increasingly popular practice
FDA Approves Novel Leg Prosthesis for AKAs
New device adheres to the leg with fixtures and screws implanted into the remaining thigh bone
FDA Approves Rexulti for Schizophrenia, Depression
But shouldn't be prescribed to some older people
![Iressa (gefitinib) has been approved by the U.S. Food and Drug Administration to treat patients with metastatic non-small-cell lung cancer with a specific genetic mutation (epidermal growth factor receptor [EGFR]). A just-approved companion diagnostic test can identify patients who could benefit from this new use.](https://www.ehealth-news.com/wp-content/uploads/2016/01/fdalogo-6-180x84.jpg "FDA Approves Iressa for EGFR+ Metastatic Lung Cancer")
FDA Approves Iressa for EGFR+ Metastatic Lung Cancer
New companion diagnostic kit can identify candidates
